Best of heart failure

61 management of t making. The patie compassionate bas benefits and side e their parents. 2 Methods We evaluated pa institution for who February 2008 to pharmacy databas starting the medi POTS was specifi heart rate increase 120 bpm within t with symptoms significant orthost age at commence up-titration, reaso treatment, medica medications with worsening of sym and at follow-up cardiogram (EKG dine and at follo 2.1 Statistical An Normally distribut and standard devi were described w pendent t test was nificant level was Table 1 Demographi clinician’s stated indi starting ivabradine 60 for POTS were evaluated. Animal studies and articles written in languages other than English were excluded. The titles and abstracts of the search results were first screened for possible inclusion. The full texts of these reports were then reviewed to determine final eligibility for inclusion in the systematic review. Authors (MEG and AKW) indepen- dently performed the literature review and study selection. Any disagreements were resolved by a third author (JNB). 2.3 Data Extraction Authors, publication date, study desig n, study location, patient demographics, ivabradine treatment dose and dura- tion, prior medication use for treatment of POTS, con- comitant medication treatment regimens, clinical outcomes including subjective (improvement of symptoms) and objective (change in HR) measures, and ivabradine-related adverse drug events were extracted from each included study using a standardized data extraction process. 3 Results 3.1 Study Selection Figure 1 describes the literature search. Initially, 73 articles were identified. After screening titles and abstracts and removing dup reviewed to consisted of t spective cohor use for POTS summary of i studies, and c 3.2 Literatur Barzilai and single-dose, patients with [ 13 ]. Orthosta of at least 30 more than 2 during a hea rences. Patien nancy, uncont history of syst function. Eig recruited wit 31 ± 3 years, duration of P participants taking propra ticipants were MEDLINE (n=19) Records after dup removed (n=6 Titles and abstracts (n=61) Full text articles ass eligibility (n=4 Articles include qualitative analysis Identi�ication Screening Eligibility Included Fig. 1 Flow diagram for reference search and selection of articles for analysis Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome 20. Khan S, Hamid S, Rinaldi C. Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker. Pac Clin Electrophysiol. 2009;32:131–3. 21. Oztunc F, Ugan Atik S, Dedeoglu R, Erbek Alp F, Gokalp S. Cooccurrence of postural orthostatic tachycardia syndrome with two different clinical entities. Case Rep Pediatr. 2016;2016:8542158. 22. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med J. 2010;4:166–7. 23. Jamil-Copley S, Nagarajan DV, Baig MK. Use of ivabradine in postural orthostatic tachycardia syndrome. J Atr Fibrillat. 2010;2:745–6. 24. Ewan V, Norton M, Newton JL. Symptom improvement in pos- tural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007;9:1202. 25. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:308–13. 26. Riccioni G. Ivabradine: an intelligent drug for the tr atment of ischemic heart disease. Molecules. 2012;17:13592–604. 27. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and out- comes in chronic heart failure (SHIFT): a randomised placebo- controlled study. Lancet. 2010;376:875–85. 28. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16. 29. Ivabradine. In: Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. Available at: http://online.lexi.com . Accessed October 10, 2017. 204 M. E. Gee et al.